News
Omburtamab resubmitted with the FDA for CNS/leptomeningeal metastasis from neuroblastoma.- Y-mAbs Therapeutics
The submission is based on the safety and efficacy results of the pivotal Phase II studies 101 and 03-133, which the Company expects to publish later this year. Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
Condition: Neuroblastoma
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.